China Opens Regulatory Review of Novo Nordisk’s Oral Wegovy in Major Obesity Drug Race

Shanghai, August 29, 2026: China has taken an important regulatory step toward potentially allowing Novo Nordisk’s oral version of Wegovy to enter its rapidly expanding obesity-treatment market.

The Danish pharmaceutical company said China’s drug regulator has accepted its marketing application for the tablet version of Wegovy, a GLP-1 medicine containing semaglutide. The acceptance means the application can proceed through China’s regulatory review process, but it does not mean the medicine has already received final marketing approval.

A New Chapter for Wegovy in China

Wegovy has become one of the world’s best-known prescription treatments for weight management. Its active ingredient, semaglutide, belongs to the GLP-1 class of medicines, which can influence appetite and blood-sugar regulation.

The tablet formulation could offer an alternative for people who are uncomfortable with injectable treatments. Novo Nordisk and other pharmaceutical companies are therefore increasingly looking toward oral medicines as a way to broaden access to obesity treatment.

The Chinese filing is particularly significant because China represents one of the world’s largest potential markets for obesity therapies.

Competition Is Intensifying

Novo Nordisk is not entering the Chinese oral obesity market alone.

Eli Lilly has already submitted an application for its once-daily oral obesity medicine, orforglipron. The company filed its application with Chinese regulators at the end of 2025 and has been moving ahead of Novo Nordisk in the country’s race for oral weight-loss treatments.

Other major pharmaceutical companies, including Pfizer, are also developing or pursuing opportunities in the GLP-1 market, while China’s Innovent Biologics is another important competitor.

The competition means that regulatory timing, manufacturing capacity, pricing and clinical evidence could all influence which companies gain an early advantage.

China’s Obesity Market Has Significant Potential

The growing prevalence of overweight and obesity is one of the major factors attracting pharmaceutical companies to China.

China’s National Health Commission has previously projected that the proportion of people who are overweight or obese could exceed 65% by 2030, highlighting the potential scale of demand for effective weight-management treatments.

Analysts also expect China’s market for GLP-1 medicines used specifically for weight management to expand considerably. J.P. Morgan’s China healthcare research head, Yang Huang, has estimated that sales could rise to approximately 30 billion yuan ($4.46 billion) over the next five to seven years, compared with an estimated 3 billion to 4 billion yuan currently.

Tablets Could Remove an Important Barrier

Injectable medicines have transformed obesity treatment, but injections are not attractive to every patient.

An oral formulation could make treatment more acceptable to people who dislike needles or prefer taking medication in tablet form. This potential convenience is one reason Novo Nordisk and Eli Lilly are competing aggressively in the emerging oral GLP-1 category.

However, a tablet does not automatically mean that treatment will be appropriate for everyone. Prescription obesity medicines require medical evaluation, and their use depends on individual health circumstances and regulatory indications.

Novo Nordisk Faces a Strong Rival

Eli Lilly currently has an important first-mover position in China’s oral obesity-drug race.

Its orforglipron belongs to the GLP-1 class but differs from semaglutide in its molecular characteristics. Lilly has already pursued Chinese regulatory review, while Novo Nordisk has now formally entered the process with oral Wegovy.

The competition reflects a broader transformation in the global obesity-treatment industry, where pharmaceutical companies are moving beyond injectable medicines and developing easier-to-use alternatives.

Regulatory Review Still Lies Ahead

The acceptance of Novo Nordisk’s application should not be confused with final authorization.

Chinese regulators must still evaluate the submitted evidence before deciding whether the oral medicine can be marketed in the country. Novo Nordisk has not provided a firm timetable for a possible Chinese launch and has said it respects the regulatory review process.

That means the exact timing of commercial availability remains uncertain.

China’s Broader Healthcare Strategy

The development also fits into China’s broader effort to expand access to innovative medicines while strengthening regulatory pathways.

For multinational pharmaceutical companies, faster and more predictable regulatory processes can make China an increasingly important market for new treatments. For patients, the arrival of additional competitors could eventually create more treatment choices.

Pricing and reimbursement will also matter. Even if a medicine receives regulatory approval, affordability and access can influence how widely it is used.

A Potential Turning Point for Oral Obesity Treatments

Novo Nordisk’s Chinese application represents more than a single product filing. It highlights how quickly the global obesity-treatment industry is changing.

GLP-1 medicines have already reshaped the pharmaceutical market, and the next stage of competition is increasingly focused on making these therapies available in forms that patients may find easier to use.

For China, the regulatory review of oral Wegovy could become an important development in the country’s rapidly evolving obesity-treatment landscape.

For Novo Nordisk, meanwhile, the filing provides an opportunity to strengthen its position against Eli Lilly and other competitors in one of the world’s largest pharmaceutical markets.

The next major milestone will be the regulator’s eventual decision on whether oral Wegovy can be marketed in China.